Dexcom's chief financial officer Jereme Sylvain and investor‑relations head Joe Deltorchio presented the company's long‑range strategy at the Wells Fargo 21st Annual Healthcare Conference.
The medical‑device maker, valued at about $31.9 billion, was trading near $84.50 per share, with Wall Street analysts assigning price targets between $79 and $115 and a consensus "Buy" rating. Dexcom's plan calls for more than 10% annual revenue growth through 2029 and roughly 150 basis points of margin expansion each year from the 2025 baseline. The firm reported revenue growth of approximately 15.5% over the past twelve months, a gross profit margin of 62.5% and a return on equity of 38%. Street forecasts for 2027 anticipate around 11% growth, aligning with the lower end of Dexcom's outlook.
On the patient side, Dexcom highlighted the opportunity in type‑2 non‑insulin (NIT) diabetes care. While over half a billion people worldwide have diabetes, only about 2% currently use continuous glucose monitoring (CGM). Roughly 7 million NIT patients are covered commercially, representing about 25% of that segment. Management said achieving 70% coverage is a critical threshold and has submitted a proposal to the Centers for Medicare & Medicaid Services (CMS) to extend coverage to all type‑2 NIT patients. Dexcom expects Medicare approval by mid‑2027, assuming an 18‑month review cycle, and projects that inclusion in Medicare Advantage could lift total coverage to roughly 75%.
Product updates were also detailed. The FDA‑approved 15‑day sensor, cleared six to seven months ago, is expected to reach about 50% penetration of the U.S. G‑Series population by the end of 2026 and is fully integrated with major pump partners, including the G7. Production of the G6 sensor will cease in the second quarter of 2026, with only a single‑digit percentage of users remaining on existing inventory. Dexcom's over‑the‑counter Stelo CGM generated roughly $100 million in its first year and now produces $35‑$42 million in quarterly revenue, bolstered by an AI‑driven coaching feature and integrations with Apple HealthKit, Google Health Connect and Oura.
Looking ahead, the company is in design lock for its G8 platform, with firmware and software development underway and clinical trials slated to begin soon. Launch is targeted for late 2027 or early 2028, and the system will support dual‑analyte monitoring, prioritizing potassium and ketones. A hospital‑focused CGM is also planned for the end of 2027, aimed at addressing an estimated 14 million dysglycemic events annually in U.S. hospitals.
Finally, Dexcom noted that a ramp‑up at its Ireland manufacturing facility will create a gross‑margin headwind in early 2027 as costs shift from operating expenses to cost of goods sold in the fourth quarter of 2026. Management expects the adoption of the 15‑day sensor and operating leverage to offset this impact over time.
